Compare IBEX & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | CCCC |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.6M | 404.7M |
| IPO Year | 2017 | 2020 |
| Metric | IBEX | CCCC |
|---|---|---|
| Price | $29.82 | $4.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $35.00 | $12.20 |
| AVG Volume (30 Days) | 100.4K | ★ 2.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.26 | 16.45 |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $558,273,000.00 | $35,947,000.00 |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $11.83 | ★ N/A |
| Revenue Growth | ★ 9.77 | 1.02 |
| 52 Week Low | $25.94 | $1.36 |
| 52 Week High | $42.99 | $4.60 |
| Indicator | IBEX | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 62.85 |
| Support Level | $29.08 | $2.13 |
| Resistance Level | $30.30 | N/A |
| Average True Range (ATR) | 1.26 | 0.37 |
| MACD | -0.23 | 0.06 |
| Stochastic Oscillator | 25.31 | 70.09 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.